An observational study in Hyperuricemia and Healthy, sponsored by National Defense Medical Center, Taiwan. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-09.
Sponsored by National Defense Medical Center, Taiwan · Observational
Among 14 studies in Hyperuricemia with a site in Taiwan — 1 open to participants now, 1 under way, none of them phase 3. Hyperuricemia · Taiwan.
Among the 14 studies in Hyperuricemia with a site in Taiwan, this one is the only one that started in 2018, is one of 3 observational ones, and was the 5th registered.
240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.
This study's planned enrollment of 18,000 is above the median of 183 across 40 observational studies indexed under Hyperuricemia.
Browse Hyperuricemia studies →1 of the 14 studies in Hyperuricemia with a site in Taiwan is open now, in 2 countries. Each count lists the studies.
Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 take children under 18; 6 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2018.
Median enrollment 120 across the 9 interventional studies, 210 across the 3 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
6 of 14 have an industry lead sponsor. The 9 most frequent:
National Defense Medical Center, Taiwan is the lead sponsor of 64 studies on the registry; 17 are open to participants now.
National Defense Medical Center, Taiwan has 3 studies filed under Hyperuricemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hyperuricemia with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
Hyperuricemia is associated with the prevalence of metabolic syndrome and cardiovascular risks in diverse of the population. Whether the dose-response effects on the prevalence of metabolic syndrome and cardiometabolic risks is unclear. The present study is conducted to investigate the relationship between serum uric acid and the prevalence metabolic syndrome and left ventricular hypertrophy.
Apparently healthy individuals with an estimated screening number of approximately twenty-thousand individuals undergo an annual health exam in the investigators' hospital. The routine exam includes measurements of body height, body weight, blood pressure, visual and acoustic acuity, physical examinations, basic blood tests, urine analyses, chest radiography, and electrocardiography. The blood tests were performed after individuals fasted for at least eight hours. Individuals with any abnormal results underwent a clinical examination at an outpatient department for safety issues, ensuring the accuracy of the data. All data were registered prospectively. The investigators retrospectively collected data from the annual exam.
Apparently healthy individuals routinely underwent the annual health exam.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Hyperuricemia is defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in women
Diagnostic Test: Hyperuricemia
Hyperuricemia vs. normouricemia
The prevalence of metabolic syndrome
Based on the Taiwan criteria, metabolic syndrome must fulfill at least three of the five following criteria: 1) waist circumference more than 90 cm in men or more than 80 cm in women; 2) blood pressure of more than 130 / 85 mm Hg or already on anti-hypertensive medication; 3) fasting glucose of 100 mg/dl or more or already on anti-diabetic agents; 4) triglyceride level of 150 mg/dl or more or already on lipid lowering therapy for hypertriglyceridemia; 5) high-density lipoprotein cholesterol of 40 mg/dl or less in men or 50 mg/dl or less in women; the investigators also replaced the criterion of waist circumference by body mass index of 27 kg/m2 in the definition of metabolic syndrome.
Time frame: 1 day
Left ventricular hypertrophy - Cornell voltage criteria.
Left ventricular hypertrophy is defined by Cornell voltage criteria.
Time frame: 1 day
Left ventricular hypertrophy - Cornell voltage product.
Left ventricular hypertrophy is defined by Cornell voltage product.
Time frame: 1 day
Left ventricular hypertrophy - Sokolow-Lyon criteria.
Left ventricular hypertrophy is defined by Sokolow-Lyon criteria.
Time frame: 1 day
Left ventricular hypertrophy - Minnesota Code electrocardiographic classification.
Left ventricular hypertrophy is defined by Minnesota Code electrocardiographic classification.
Time frame: 1 day
Left ventricular hypertrophy - composite of Cornell voltage criteria, Cornell voltage product, Sokolow-Lyon criteria, Minnesota Code electrocardiographic classification.
Any of above left ventricular hypertrophy criteria is counted as left ventricular hypertrophy.
Time frame: 1 day
brief symptom rating scale-5
Brief symptom rating scale-5 consisted of five items with a total score of 0 to 20. Each items range from 0 to 4 in score, including difficult in falling asleep, anxiety (feeling tense or high-strung), hostility (feeling easily annoyed or irritated), interpersonal sensitivity (feeling inferior to others), depression (feeling depressed or in a low mood) in the past week. The summation of brief symptom rating scale-5 is further classified as normal (score of \<6), mild mood disorder (score of 6-9), moderate mood disorder (score of 10-14), severe mood disorder (score of \>14). Suicidal attempt is an additional item and the score \>1 is considered as severe mood disorder.
Time frame: 1 day
Plan to share: No
Started Mar 2018 (actual). Primary completion is estimated for Dec 2020, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Defense Medical Center, Taiwan